Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Guilherme Pessoa-Amorim

MD

DPhil Student | Clinical Research Fellow

Harnessing big data sources on medications for randomised controlled trials

Guilherme is a DPhil student at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU).

His DPhil project is funded by the Medical Research Council and will determine the feasibility of using routinely collected data on drugs dispensed to patients as a primary source of information about medications for participants in large-scale randomised controlled trials.  

The recently released NHS Digital dataset on medicines dispensed in the community in England represents an extraordinary opportunity to bring the worlds of clinical care and clinical research closer together. Nonetheless, it is first crucial to explore this dataset in detail, namely how it is produced, its technical features, and its coverage. Then, it is important to understand how these data compare to other similar sources of data on medications, and finally whether it is feasible to incorporate it in medical research, and in clinical trials in particular. 

Guilherme began his academic career in 2019 when he joined CTSU to work in the AMALFI trial, a study which aims to shed light on the burden of subclinical atrial fibrillation in elderly high-risk patients. He is also part of the clinical team for the ORION-4 trial, a study which is assessing the effect of inclisiran, a novel cholesterol-lowering therapy, on cardiovascular events on patients with established atherosclerotic disease. More recently, he joined the RECOVERY trial, the largest randomised controlled trial of new treatments for patients hospitalised with COVID-19.